<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MEGESTROL ACETATE</span><br/>(me-jess'trole)<br/><span class="topboxtradename">Megace, Megace ES<br/></span><b>Classifications:</b> <span class="classification">antineoplastic</span>; <span class="classification">hormone and synthetic substitute</span>; <span class="classification">progestin</span><br/><b>Prototype: </b>Progesterone<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>40 mg/mL, 125 mg/mL suspension; 20 mg, 40 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Progestational hormone with antineoplastic properties. Mechanism of action unclear; however, an antiluteinizing effect mediated
         via the pituitary has been postulated.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Moderate disease effects. Local effect when instilled directly into the endometrial cavity.</p>
<h1><a name="uses">Uses</a></h1>
<p>Palliative agent for treatment of advanced carcinoma of breast or endometrium. AIDS-related wasting or cachexia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Diagnostic test for pregnancy; use in neoplastic diseases other than cancer of endometrium and breast; first 4 mo of pregnancy
         (category X).
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Palliative Treatment for Advanced Breast Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40 mg q.i.d.<br/><br/><span class="indicationtitle">Palliative Treatment for Advanced Endometrial Cancer</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 40320 mg/d in divided doses<br/><br/><span class="indicationtitle">Appetite Stimulation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 200 mg q6h<br/><br/><span class="indicationtitle">HIV-Related Cachexia</span><br/><span class="rdage">Adult::</span> <span class="rdroute">PO (suspension)</span> 800 mg q.d. or 625 mg of <b>Megace ES</b>
<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give with meals or food if GI distress occurs.</li>
<li>Shake oral suspension well before use.</li>
<li>Store at 15°30° C (59°86° F) in tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Urogenital:</span> Vaginal bleeding. <span class="typehead">Body as a Whole:</span> Breast tenderness, headache, increased appetite, weight gain, allergic-type reactions (including bronchial asthma). <span class="typehead">GI:</span> Abdominal pain, nausea, vomiting. <span class="typehead">Hematologic:</span> DVT. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> May increase levels of <b>warfarin;</b> may decrease renal clearance of <b>dofetilide.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Appears to be well absorbed from GI tract. <span class="typehead">Onset:</span> Onset of objective response in breast cancer in 68 wk. <span class="typehead">Peak:</span> 13 h. <span class="typehead">Duration:</span> 312 mo. <span class="typehead">Metabolism:</span> Completely metabolized in liver. <span class="typehead">Elimination:</span> 5778% of dose excreted in urine within 10 d. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor weight periodically.</li>
<li>Notify physician if abdominal pain, headache, nausea, vomiting, or breast tenderness become pronounced.</li>
<li>Monitor for allergic reactions, including breathing distress characteristic of asthma, rash, urticaria, anaphylaxis, tachypnea,
            anxiety. Stop medication if they appear and notify physician.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use contraception measures during therapy for carcinoma.</li>
<li>Learn breast self-examination.</li>
<li>Learn S&amp;S of thrombophlebitis (see Appendix F).</li>
<li>Review package insert to ensure understanding of megestrol therapy.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>